授權使用與披露受保護的健康資訊 (PHI) 之指示 1. 完成此表單上的所有部分。不接受未完成的表單。 2. 列出向您提供記錄的提供者/實體並按下表的說明提交。 3. 如果要加入酒精/藥物治療、心理健康治療、基因資訊或保密 HIV 相關資訊，則在第一項下各個相關類型旁簽署姓名首字母。 • 酒精或藥物治療資訊是指來自酒精/藥物治療計畫的任何資訊。 • 心理健康治療資訊是指可識別受紐約州法律保護的心理健康患者身分的臨床記錄或臨床資訊。 • 保密 HIV 相關資訊是指顯示您曾有 HIV 相關檢測、感染或疾病（包括 AIDS），或曾接觸 HIV 的資訊。這包括陰性結果。 • 基因資訊是指診斷是否存在與基因疾病或殘障相關的遺傳變異傾向的實驗室測試，包括 DNA 圖譜分析。 完成請求之前會提供費用估計（如果有）。 場所 地址 電話號碼 Tisch, Kimmel, Hassenfeld Children's Hospital, Rusk Rehabilitation, Ambulatory Care Center NYU Langone Health HIM Department 親自到場：550 First Avenue, Lobby, NY, NY 10016 郵寄：One Park Avenue, 3rd Floor, NY, NY 10016 212 263 5490 NYU Langone Orthopedic Hospital NYU Langone Orthopedic Hospital HIM Department 親自到場：380 2nd Avenue, Suite 640 NY, NY 10003 郵寄：301 E 17th St, NY, NY 10003 212 598 6790 NYU Langone Hospital Long Island NYU Langone Hospital Long Island HIM Department 親自到場：Admitting Office Main Lobby 259 First Street, Mineola, NY 11501 郵寄：200 Old Country Road, Suite SW 201 Mineola, NY 11501 516 663 2515，選項 4 Laura & Isaac Perlmutter Cancer Center Perlmutter Cancer Center HIM Department 160 E 34th Street NY, NY 10016 212 731 6180 NYU Langone Hospital Long Island Laura & Isaac Perlmutter Cancer CenterPerlmutter Cancer Center HIM Department 120 Mineola Blvd, 6th Floor Mineola, NY 11501 516 633 8250 NYU Langone Hospital Brooklyn NYU Langone Hospital Brooklyn HIM Department 150 55th Street Brooklyn, NY 11220 718 630 7125 NYU Grossman School of Medicine Faculty Group Practices (FGP) 直接前往個別辦公室 直接聯絡個別辦公室 Family Health Centers at NYU Langone Marilyn Vientos, Director FHC Network Operations FHCPatientRelations@nvulangone.org 直接聯絡個別辦公室 NYU Langone Hospital Long Island Certified Home Health Agency (CHHA) NYU Langone Hospital Long Island CHHA 290 Old Country Road Mineola, NY 11501 516 663 8000 Southwest Brooklyn Dental Practice Attn:Practice Manager 215 54th Street Brooklyn, NY 11220 929 455 2099 Radiology Films/Images (放射科膠片/影像) Tisch：560 1st Ave, 2nd Floor, NY, NY 10006 骨科醫院：301 East 17th St, Suite 600/6th Floor, NY, NY 10003 FGP 放射科：NYU Langone Health Radiology Medical Records, 650 First Avenue, 4th Floor, NY, NY 10016 所有其他地點：直接前往影像研究的地點 Tisch：212 263 5227 骨科：212 598 6373 FGP：212 263 7108 其他：直接聯絡個別辦公室 Long Island Community Hospital (LICH) Long Island Community Hospital HIM Department 101 Hospital Road, Patchogue, NY 11772 631 654 7710 第 1 頁，共 2 頁 （2019 年 8 月） NYU Langone Health NYU Langone Hospitals Family Health Centers @NYU Langone NYU Grossman School of Medicine Long Island Community Hospital @NYU Langone Health 授權使用與披露受保護的健康資訊 (PHI) 患者姓名 患者出生日期 電話號碼 患者住址 我，或我的授權代表，要求根據此表單的說明披露與我的護理和治療相關的健康資訊。我理解： 1. 除非我提供明確許可，否則不得共享有關酒精/藥物治療、心理健康治療、基因檢測的資訊，和/或 HIV* 相關保密資訊。在下方簽署我的姓名首字母縮寫，即表示我特別授權將此類資訊披露給此表單上指示的人員。 酒精或藥物治療資訊（酒精/藥物治療計畫的記錄） 心理健康治療資訊（需要額外授權的心理療法註釋除外） 基因檢測資訊 HIV/AIDS 相關資訊（如應法律要求披露，須於披露此類資訊時註明禁止再披露的相關聲明） 2. 除上面列出的特殊類型資訊外，因為此授權而共享的資訊可由被接收者再次共享，且不再受聯邦或州法律的保護。除非聯邦或州法律允許，否則即使我授權共享 HIV 相關資訊，接收者也不能在未獲得我許可的情況下共享此類資訊。我可以要求取得在沒有授權的情況下得以接收或使用我的 HIV 相關資訊的人員名單。如果我因 HIV 相關資訊遭公佈或披露而受到歧視，我可以透過 (212) 480 2493 聯絡紐約州人權處 (New York State Division of Human Rights) 或透過 (212) 306 7450 聯絡紐約市人權委員會 (New York City Commission of Human Rights)。以上機構負責保障我的權利。 3. 我可書面通知接收我提交表單的提供者/實體撤銷此授權（依據說明頁中的地址）。此撤銷將生效，但是 NYU Langone Health 和/或 Long Island Community Hospital（「LICH」）已據此授權所行之事不受限制。 4. 簽署此授權書是自願的。除部分特殊限制情況下，NYU Langone Health 或 LICH 不得以我是否簽署此授權書作為獲得治療、付款、投保健康計畫的條件，或是作為獲得福利的資格。 5. 如果我索取放射科膠片原件，我理解 NYU Langone Health 不會保留任何此膠片（類比）複本。我免除 NYU Langone Health 因維護我的影像記錄而承擔的所有責任。 您想要對其披露資訊之提供者/實體的名稱和地址（見說明頁）： 第 2 頁，共 2 頁 （2019 年 8 月） NYU Langone Health NYU Langone Hospitals Family Health Centers @NYU Langone NYU Grossman School of Medicine Long Island Community Hospital @NYU Langone Health 資訊披露的目的： □ 應我要求 □ 持續護理 □ 其他（請說明，包括是否為政府福利或計畫所需）：_______________________________________________________________ 接收此資訊的人士： □ 自己 □ 其他人 （姓名；收取資訊時所需的身分證件）： _____________________________________________________ 表單/格式（可能需收取費用；披露前會提供預估費用）： □ 紙本郵寄至： ______________________________________________________________________________________________ □ 收取，紙本 □ MyChart（60 天內可供下載） □ 傳真（號碼）：_________________________________□ CD/DVD □ USB □ 安全電子郵件（30 天內可供存取/下載）： _______________________________________________________________________ □ 其他： ____________________________________________________________________________________________________ 要披露的資訊說明： □ 上述提供者/實體提供的完整醫療記錄 □ 與以下日期相關的記錄： ____________________________________________________________________________________ □ 放射科報告（列出檢查類型和日期）： _________________________________________________________________________ □ 放射科膠片/影像（列出檢查類型和日期）：_____________________________________________________________________ □ 與以下日期相關資訊的摘要（總結）： _________________________________________________________________________ □ 由非 NYU Langone Health 提供者傳送到上述提供者/實體，並由 NYU Langone Health 保存以在我的護理中使用的記錄 □ 其他（例如帳單記錄；知情同意書）： _________________________________________________________________________ 除非此處另有說明（具體事件或日期），否則授權將於簽名日期起一 (1) 年後終止： 我的所有問題（如有）均已得到回答。此外，如果 NYU Langone Health 和/或 LICH 要求我填寫此表單，我已獲得此表單的複本。 簽名︰ 日期： 時間：上午/下午 （患者或獲授權簽名的人員） 如果同意授權者非患者本人，請正楷書寫姓名並註明簽名授權類型。 如院方提出要求，應提供證明文件。 姓名/授權： *導致 AIDS 的人類免疫缺乏病毒。《紐約州公共衛生法》(New York State Public Health Law) 保護可合理識別有 HIV 癥狀或感染的人的資訊以及與此人相關的聯絡資訊。 僅限辦公室使用：MRN： 已收到： / / 姓名首字母縮寫：


Otorizasyon pou Itilize ak Pataje Enfòmasyon Sante Pwoteje (Protected Health Information, PHI) Enstriksyon yo 1. Ranpli tout seksyon nan fòm sa a. Nou p ap aksepte fòm ki pa fin ranpli nèt. 2. Mete non ajans/enstitisyon w ap mande dosye nan men li (yo) epi soumèt li (yo) jan yo di sa nan tablo ki anba a. 3. Si sipoze genyen enfòmasyon konsènan Tretman pou Alkòl/Dwòg, Tretman pou Pwoblèm Mantal, Enfòmasyon jenetik, oswa enfòmasyon sekrè ki gen pou wè ak VIH, mete inisyal nou akote chak kalite enfòmasyon anba nimewo an. • Enfòmasyon konsènan Tretman pou Alkòl/Dwòg vle di nenpòt enfòmasyon ki sòti nan yon pwogram tretman alkòl/dwòg. • Enfòmasyon konsènan Tretman Pou Pwoblèm Mantal vle di dosye klinik oswa enfòmasyon klinik ki gen tandans idantifye pasyan sante mantal, ki gen pwoteksyon sou Lwa Eta New York. • Enfòmasyon sekrè ki gen pou wè ak VIH vle di nenpòt enfòmasyon ki montre ou te fè yon tès pou VIH, enfeksyon, oswa maladi (tankou SIDA), oswa ou te pran kontak ak VIH. Sa gen rezilta negatif ladan yo tou. • Enfòmasyon jenetik vle di nenpòt tès nan laboratwa pou dyagnostike prezans yon varyasyon jenetik ki gen pou wè ak yon predispozisyon pou yon maladi oswa andikap jenetik, tankou analiz pwofil ADN. Y ap ba ou yon estimasyon frè yo, si genyen, avan ou fini ak demand lan. Sit Adrès Nimewo Telefòn Tisch, Kimmel, Hassenfeld Children’s Hospital, Rusk Rehabilitation, Ambulatory Care Center NYU Langone Health HIM Department Pou vizit an pèsòn: 550 First Avenue, Lobby, NY, NY 10016 Atravè lapòs: One Park Avenue, 3rd Floor, NY, NY 10016 212 263 5490 NYU Langone Orthopedic Hospital NYU Langone Orthopedic Hospital HIM Department Pou vizit an pèsòn: 380 2nd Avenue, Suite 640 NY, NY 10003 Atravè lapòs: 301 E 17th St, NY, NY 10003 212 598 6790 NYU Langone Hospital Long Island NYU Langone Hospital Long Island HIM Department Pou vizit an pèsòn: Biwo Admisyon an Antre Prensipal la 259 First Street, Mineola, NY 11501 Atravè lapòs: 200 Old Country Road, Suite SW 201 Mineola, NY 11501 516 663 2515, opsyon 4 Laura & Isaac Perlmutter Cancer Center Perlmutter Cancer Center HIM Department 160 E 34th Street NY, NY 10016 212 731 6180 NYU Langone Hospital Long Island Laura & Isaac Perlmutter Cancer Center Perlmutter Cancer Center HIM Department 120 Mineola Blvd, 6th Floor Mineola, NY 11501 516 633 8250 NYU Langone Hospital Brooklyn NYU Langone Hospital Brooklyn HIM Department 150 55th Street Brooklyn, NY 11220 718 630 7125 NYU Grossman School of Medicine Faculty Group Practices (FGP) Ale nan biwo a dirèkteman Kontakte biwo endividyèl la dirèkteman Family Health Centers at NYU Langone Marilyn Vientos, Direktris Fonksyònman Rezo FHC yo FHCPatientRelations@nvulangone.org Kontakte biwo endividyèl la dirèkteman NYU Langone Hospital Long Island Certified Home Health Agency (CHHA) Marilyn Vientos, Director FHC Network Operations 290 Old Country Road Mineola, NY 11501 516 663 8000 Pratik Dantè (Dental Practice) Southwest Brooklyn Attn: Manadjè Pratik (Practice Manager) 215 54th Street Brooklyn, NY 11220 929 455 2099 Fim/Imaj Radyoloji (Radiology Films/Images) Tisch: 560 1st Ave, 2nd Floor, NY, NY 10006 Lopital Òtopedik (Orthopedic Hospital): 301 East 17th St, Suite 600/6th Floor, NY, NY 10003 Radyoloji FGP: Rejis Medikal sou Radyoloji (Radiology Medical Records) NYU Langone Health yo, 650 First Avenue 4th Floor New York, NY 10016 Tout lòt kote: dirèkteman kote yo fè etid imajri an Tisch: 212 263 5227 Òtopedik: 212 598 6373 FGP: 212 263 7108 Lòt: kontakte biwo endividyèl a dirèkteman Long Island Community Hospital (LICH) Long Island Community Hospital HIM Department 101 Hospital Road, Patchogue, NY 11772 631 654 7710 Paj 1 sou 2 (08/19) NYU Langone Health NYU Langone Hospitals Family Health Centers @NYU Langone NYU School of Medicine Long Island Community Hospital @NYU Langone Health OTORIZASYON POU ITILIZE AK PATAJE ENFÒMASYON SANTE PWOTEJE (PROTECTED HEALTH INFORMATION, PHI) Non Pasyan an Dat Nesans Pasyan an Nimewo Telefòn Adrès Pasyan an Mwen menm, oswa reprezantan otorize mwen, mande pou pataje enfòmasyon sante konsènan swen ak tretman mwen jan li dekri nan fòm sa a. Mwen konprann: 1. Yo pa pral pataje enfòmasyon konsènan TRETMAN POU ABI ALKÒL/DWÒG, TRETMAN POU PWOBLÈM MANTAL, TÈS JENETIK, ak/oswa ENFÒMASYON SEKRÈ KI GEN POU WÈ AK VIH amwenske mwen bay pèmisyon pou sa espesyalman. Depi mwen mete inisyal mwen anba a, mwen bay otorizasyon espesyalman pou pataje enfòmasyon sa yo ak moun non li, oswa non yo, endike sou fòm sa a. Enfòmasyon Sou Tretman pou Alkòl oswa Dwòg (dosye nan pwogram pou tretman alkòl/dwòg) Enfòmasyon sou Tretman Sante Mantal (sof pou nòt sikoterapi ki ka bezwen plis otorizasyon) Enfòmasyon Sou Tès Jenetik Enfòmasyon ki gen pou wè ak VIH/SIDA (pou patajeenfòmasyon sa a fòk genyendeklarasyon nesesè konsènan entèdiksyonpou re pataje li lè lalwa egzije sa) 2. Sòf pou kalite enfòmasyon espesyal ki endike anwo a, moun ki resevwa enfòmasyon yo pataje gras ak otorizasyon sa a kapab pataje yo ankò epi lè sa a yo p ap gen pwoteksyon lwa federal oswa eta. Amwenske lwa federal oswa eta pèmèt sa, si mwen ap bay pèmisyon pou pataje enfòmasyon ki gen pou wè ak VIH, moun ki resevwa enfòmasyon an pa gendwa pataje li san pèmisyon mwen. Mwen ka mande yon lis moun ki ka resevwa oswa ki ka itilize enfòmasyon ki asosye avèk VIH mwen san otorizasyon mwen. Si yo fè diskriminasyon kont mwen paske yo te pataje oswa divilge enfòmasyon ki gen pou wè ak VIH, mwen kapab kontakte Divizyon Dwa Moun Eta New York nan 212 480 2493 oswa Komisyon Dwa Moun New York nan 212 306 7450. Ajans sa yo responsab pou pwoteje dwa mwen yo. 3. Pou anile otorizasyon sa a, mwen kapab ekri founisè/enstitisyon mwen te bay fòm nan (nan adrès ki ekri sou paj enstriksyon an). Anilasyon sa a ap vin an vigè, eksepte nan ka kote NYU Langone Health ak/oswa Long Island Community Hospital (“LICH”) te deja konte sou otorizasyon sa a. 4. Se si ou vle pou ou siyen otorizasyon sa a. NYU Langone Health oswa LICH kapab pa jere kesyon tretman, pèman, enskripsyon nan plan sante, oswa kalifikasyon pou avantaj si mwen siyen oswa mwen refize siyen otorizasyon sa a, eksepte nan kèk sikonstans limite. 5. Si m ap mande fim radyoloji orijinal yo, mwen konprann pa gen okenn kopi fim (analòg) NYU Langone Health kenbe. Mwen ap retire tout responsablite sou do NYU Langone Health pou dosye imaj mwen yo l ap konsève yo. Non ak adrès Pwofesyonèl Swen Sante/ Antite ou vle pataje enfòmasyon (gade nan paj enstriksyon an): Paj 2 sou 2 (08/19) NYU Langone Health NYU Langone Hospitals Family Health Centers @NYU Langone NYU School of Medicine Long Island Community Hospital @NYU Langone Health Rezon pou pataje enfòmasyon yo: □ Lè mwen mande sa □ Pou kontinye ban m swen □ Lòt (tanpri eksplike, tankou si se pou yon avantaj oswa pwogram leta): ___________________________________ Moun k ap resevwa enfòmasyon sa yo: □ Mwen menm □ Lòt (non moun nan, l ap bezwen yon pyès idantite pou pran li): _____________________ Fòm/Fòma (kapab gen frè; y ap ba ou yon estimasyon avan yo bay li): □ Voye papye pa lapòs bay: ________________________________________________________________ □ Pou vin chèche, sou papye □ MyChart (disponib pou telechaje pou 60 jou) □ Nimewo Faks: ___________________________ □ CD/DVD □ USB □ Imèl Sekirize (disponib pou aksè/telechaje pandan 30 jou): ____________________________________________ □ Lòt: _________________________________________________________________________________ Deskripsyon enfòmasyon pou pataje yo: □ Tout dosye medikal ki nan men ajans/enstitisyon ki anwo a □ Dosye ki gen pou wè ak dat sa yo: _________________________________________________________ □ Rapò radyoloji (mete kalite tès la ak dat la): _______________________________________________________ □ Fim/imaj radyoloji (mete kalite tès la ak dat la): ____________________________________________________ □ Rezime (apèsi) enfòmasyon pou dat sa yo: __________________________________________________ □ Dosye ajans ki pa NYU Langone Health te voye bay ajans/enstitisyon ki anwo a epi NYU Langone Health te kenbe pou itilize nan kad swen mwen yo □ Lòt (tankou dosye bòdwo, fòm konsantman) ________________________________________________________ : Otorizasyon an ap fini nan yon (1) lane apre dat yo siyen li an, amwenske dat la ekri la (dat oswa evènman espesifik): Yo te reponn kesyon mwen yo, si mwen te genyen. Epitou, yo te ban mwen oswa ofri mwen yon kopi nan fòm sa a si NYU Langone Health ak/oswa LICH te mande mwen ranpli fòm sa a. Siyati: Dat: Lè: AM/PM (Pasyan oswa moun ki gen otorizasyon pou siyen) Si moun k ap bay konsantman an se pa pasyan an, ekri non li an lèt detache ak kalite otorite li pou siyen. Ou sipoze bay dokiman sipò yo nan moman w ap fè demann nan. Non/Otorite: * Viris Iminodefisyans Imen ki lakòz SIDA. Lwa Eta New York sou Sante Piblik pwoteje enfòmasyon ki kapab idantifye yon fason rezonab yon moun kòm moun ki gen sentòm VIH oswa enfeksyon ak enfòmasyon konsènan kontak yon moun. Seksyon sa a se pou biwo a itilize sèlman: MRN: Resevwa: / / Inisyal:


What’s new in the NTM treatment guidelines?Ashwin Basavaraj, MD, FCCP, ATSFAssistant Professor of MedicineSection Chief, Pulmonary, Critical Care and Sleep MedicineBellevue Hospital CenterNYU Grossman School of MedicineOctober 28, 2020Division of Pulmonary, Critical Care and Sleep MedicineFinancial Disclosures•Consultant: Insmed, Hill Rom•Advisory Board: Insmed, Hill Rom•Clinical trial: Hill Rom22007 NTM guidelines2020 NTM guidelines2 societies•American Thoracic Society•Infectious Disease Society of America4 societies•American Thoracic Society•Infectious Disease Society of America•European Respiratory Society•European Society of Clinical Microbiology and Infectious Diseases3•22 PICO questions and 31 recommendations•Focused on MAC, M.abscessus, M.kansasii, and M.xenopi4Diagnostic criteria for NTM pulmonary disease•Remains the same for the 2007 and 2020 guidelines•Require both clinical and radiographic criteria for NTM•Exclusion of other diagnosis•Microbiologic criteria:1.Positive culture results from at least two separate sputum samples, or2.Positive culture from at least one bronchial wash or lavage, or3.Transbronchial or other lung biopsy with mycobacterial histologic features and positive culture for NTM or biopsy showing mycobacterial histologic features and one or more sputum or bronchial washings that are culture positive for NTM5Treatment of NTM pulmonary disease•In patients who meet diagnostic criteria for NTM pulmonary disease, we suggest initiation of treatment rather than watchful waiting, especially in the setting of positive AFB smears and/or cavitary disease (conditional recommendation, very low certainty in estimates of effect).6Progression of NTM Pulmonary DiseaseIn Those Who Meet ATS/IDSA Diagnostic Criteria488 with MAC PD(per ATS)551 with MAC PD (per ATS)62.Progressed 58.Treated41.No treatment23. Stable51.52. Spontaneouslyculture convertedHwang JA et al. Eur Respir J. 2017 Byoung SK et al. Resp Med. 2019Who to Treat?Risk Factors Associated with ProgressionHost/Demographic Factors• Male gender• Older age• Presence of comorbidities• Low body mass indexLaboratory Factors• Elevated inflammatory indices (ESR, CRP)• Anemia• HypoalbuminemiaRadiographic Factors• Fibrocavitary• Extent of diseaseMicrobial Factors• Bacterial load• SpeciesHwang JA et al. Eur Respir J. 2017 Kwon BS et al. Resp Med. 2019Moon SM et al. Resp Med. 2019•For patients with MAC or m.abscessus, we suggest susceptibility based treatment for macrolides and amikacin (conditional recommendation, very low certainty in estimates of effect).9Antimicrobial AgentMIC, ug/mLCommentsSIRFirst LineClarithromycin≤ 816*≥ 32Class drug for macrolidesAmikacin (IV)≤ 1632≥64Amikacin(liposomal inhaled)≤ 64 ≥ 128Woods et al, CLSI Supplement, 2018.Treatment of macrolide susceptible MAC •We recommend a 3 drug regimen that includes a macrolide over a 3 drug regimen without a macrolide (strong recommendation, very low certainty in estimates of effect).10Griffith DE et al. Am J Respir Crit Care Med. 2006 Wallace R et al. Chest. 2014Jeong BH et al. Am J Respir Crit Care Med. 2015Koh WJ et al. Eur Respir J. 2017Moon SM et al. Eur Respir J. 2016Morimoto K et al. Ann Am Thorac Soc. 2016Treatment of macrolide susceptible MAC •We suggest azithromycin based treatment regimens rather than clarithromycin based regimens (conditional recommendation, very low certainty in estimates of effect).•We suggest a treatment regimen with at least 3 drugs (including a macrolide and ethambutol) over a regimen with 2 drugs (a macrolide and ethambutol) (conditional recommendation, very low certainty in estimates of effect).11Macrolide susceptible MAC•In patients with noncavitary nodular/bronchiectatic macrolide susceptible MAC pulmonary disease, we suggest a 3 times a week macrolide based regimen rather than a daily macrolide based regimen (conditional recommendation, very low certainty in estimates of effect).•In patients with cavitary or severe/advanced nodular bronchiectasis macrolide susceptible MAC pulmonary disease, we suggest a daily macrolide based regimen (conditional recommendation, very low certainty in estimates of effect).12Inhaled liposomal amikacin•In patients with newly diagnosed MAC pulmonary disease, we suggest neither inhaled amikacin (parental) nor amikacin liposome inhalation suspension (ALIS) be used as part of the initial treatment regimen (conditional recommendation, very low certainty in estimates of effect).•In patients with MAC pulmonary disease who have failed therapy after at least 6 months of guideline based therapy, we recommend addition of ALIS to the treatment regimen rather than a standard oral regimen, only (strong recommendation, moderate certainty in estimates of effect).1314Griffith et al, AM J Resp Crit Care Med, 2018MACMacrolide sensitiveNoYesDAILYRifampinEthambutolOther drugClofazimineMoxifloxacinBedaquilineInh. amikacinOther drugs?Add IV AmikacinDuration: 12 mos culture negativity3X/weekAzithromycin*RifampinEthambutolDAILYAzithromycin*RifampinEthambutolCavities PresentNoYesTreatment of Pulmonary Mycobacterium aviumComplexGriffith DE et al. Am J Respir Crit Care Med. 2007* clarithromycin is an alternativeMajor points•Diagnostic criteria for NTM pulmonary disease remains the same.•Treatment may be preferred over watchful waiting, specifically in those who have risk factors for progression.•Azithromycin is preferred over clarithromycin.•Inhaled liposomal amikacin is approved for those with refractory MAC.•Susceptibilities can help direct treatment in NTM.16THANK YOU!17ReferencesDaley et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. EurRespir J. 2020 Jul 7;56(1):2000535. doi: 10.1183/13993003.00535 2020. Print 2020 Jul. Griffith DE, et al. An official ATS/IDSA statement:diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J RespirCrit Care Med. 2007,Feb 15;175(4):367 416.Griffith DE et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease Am J Respir Crit Care Med. 2006;174:928 934.Griffith DE et al. Amikacin Liposome Inhalation Suspension for Treatment Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open Label, Randomized Study. AM J Resp Crit Care Med. 2018 Dec 15;198(12):1559 1569. Jeong BH et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease Am J Respir Crit Care Med. 2015;191:96 103.Koh WJ et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017;50.Morimoto K et al. Macrolide Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. Ann Am ThoracSoc. 2016;11:1904Wallace R et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014;146:276 282.Woods GL, et al. Performance standards for susceptibility testing of mycobacteria, nocardia ssp, and other aerobic actinomycetes. CLSI supplement M62.


SportsPerformanceCenterContact UsCall us at 646 501 7109 or emailsportsperformancecenter@nyulangone.orgtoschedule an appointment.NYULangoneOrthopedicCenter333East38thStreet,5thFloorNewYork, NY 10016What’s Included: Kick off the program with a one on one running assessment! This will guide your training program by identifying the specific areas for you to work on for warm ups, strength and crosstraining as well as defining your individualized running program! Running Analysis We record a high definition video of your running from the front, back, and sides, and then use motion analysis software to determine how your running mechanics affect your performance. Aerobic Capacity Test (VO2max) The aerobic capacity test (VO2max) tells you the maximal rate at which your heart and lungs are able to provide oxygen to exercising muscles, and how much work your muscles are able to do while using that oxygen as the primary energy source. It is the leading indicator of aerobic fitness and health status. Following testing, you’ll learn just how efficient you are at using energy supplies for a long run, ride, or swim. You’ll also discover which energy systems you need to work on to improve your performance. Lactate Profile The lactate threshold test can help you perfect your training by determining baseline fitness and training zones to improve performance, and by tracking your training program efficacy. This will define your zone2 , tempo, threshold and interval training zones. Personalized Programming Each participant receives a detailed summary and analysis of the above test results and an extensive report with thorough, customized recommendations based on range of motion, stability, mobility and strength needs as well as biomechanic cues and drills. Join us for interactive seminars on training programming, progressions and injury prevention as well as fueling, hydration and race day prep! Enjoy weekly strength and conditioning classes to build a strong body for running efficiently, safely and successfully! Experts will take runners through a research based exercise program to target key muscles and joints proven to improve running mechanics and economy. This small group training will incorporate strengthening exercises, conditioning drills, and running form instruction. Classes: Tu/Thu 7pm